vs
Side-by-side financial comparison of Organon & Co. (OGN) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.5B, roughly 1.0× BeOne Medicines Ltd.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs -13.6%, a 18.0% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -5.3%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $96.0M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -3.6%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
OGN vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.5B |
| Net Profit | $-205.0M | $66.5M |
| Gross Margin | 49.2% | 90.5% |
| Operating Margin | -9.8% | 12.4% |
| Net Margin | -13.6% | 4.4% |
| Revenue YoY | -5.3% | 32.8% |
| Net Profit YoY | -288.1% | 143.8% |
| EPS (diluted) | $-0.78 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | $1.5B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.5B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.6B | $1.0B | ||
| Q2 24 | $1.6B | $929.2M | ||
| Q1 24 | $1.6B | $751.7M |
| Q4 25 | $-205.0M | $66.5M | ||
| Q3 25 | $160.0M | $124.8M | ||
| Q2 25 | $145.0M | $94.3M | ||
| Q1 25 | $87.0M | $1.3M | ||
| Q4 24 | $109.0M | $-151.9M | ||
| Q3 24 | $359.0M | $-121.3M | ||
| Q2 24 | $195.0M | $-120.4M | ||
| Q1 24 | $201.0M | $-251.2M |
| Q4 25 | 49.2% | 90.5% | ||
| Q3 25 | 53.5% | 86.1% | ||
| Q2 25 | 54.8% | 87.5% | ||
| Q1 25 | 55.6% | 85.2% | ||
| Q4 24 | 56.3% | 85.8% | ||
| Q3 24 | 58.3% | 83.0% | ||
| Q2 24 | 58.4% | 85.1% | ||
| Q1 24 | 59.0% | 83.4% |
| Q4 25 | -9.8% | 12.4% | ||
| Q3 25 | 15.2% | 11.5% | ||
| Q2 25 | 14.4% | 6.7% | ||
| Q1 25 | 6.7% | 1.0% | ||
| Q4 24 | 8.1% | -7.0% | ||
| Q3 24 | 13.1% | -12.0% | ||
| Q2 24 | 14.6% | -11.5% | ||
| Q1 24 | 14.5% | -34.8% |
| Q4 25 | -13.6% | 4.4% | ||
| Q3 25 | 10.0% | 8.8% | ||
| Q2 25 | 9.1% | 7.2% | ||
| Q1 25 | 5.8% | 0.1% | ||
| Q4 24 | 6.8% | -13.5% | ||
| Q3 24 | 22.7% | -12.1% | ||
| Q2 24 | 12.1% | -13.0% | ||
| Q1 24 | 12.4% | -33.4% |
| Q4 25 | $-0.78 | $0.05 | ||
| Q3 25 | $0.61 | $0.08 | ||
| Q2 25 | $0.56 | $0.06 | ||
| Q1 25 | $0.33 | $0.00 | ||
| Q4 24 | $0.42 | $-0.10 | ||
| Q3 24 | $1.38 | $-0.09 | ||
| Q2 24 | $0.75 | $-0.09 | ||
| Q1 24 | $0.78 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $574.0M | $4.5B |
| Total DebtLower is stronger | $8.6B | $836.4M |
| Stockholders' EquityBook value | $752.0M | $4.4B |
| Total Assets | $12.9B | $8.2B |
| Debt / EquityLower = less leverage | 11.49× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $574.0M | $4.5B | ||
| Q3 25 | $672.0M | $4.0B | ||
| Q2 25 | $599.0M | $2.8B | ||
| Q1 25 | $547.0M | $2.5B | ||
| Q4 24 | $675.0M | $2.6B | ||
| Q3 24 | $763.0M | $2.7B | ||
| Q2 24 | $704.0M | $2.6B | ||
| Q1 24 | $575.0M | $2.8B |
| Q4 25 | $8.6B | $836.4M | ||
| Q3 25 | $8.8B | — | ||
| Q2 25 | $8.9B | — | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.7B | — | ||
| Q2 24 | $8.7B | — | ||
| Q1 24 | $8.7B | — |
| Q4 25 | $752.0M | $4.4B | ||
| Q3 25 | $906.0M | $4.1B | ||
| Q2 25 | $733.0M | $3.8B | ||
| Q1 25 | $542.0M | $3.5B | ||
| Q4 24 | $472.0M | $3.3B | ||
| Q3 24 | $493.0M | $3.4B | ||
| Q2 24 | $144.0M | $3.4B | ||
| Q1 24 | $48.0M | $3.4B |
| Q4 25 | $12.9B | $8.2B | ||
| Q3 25 | $13.6B | $7.6B | ||
| Q2 25 | $13.5B | $6.3B | ||
| Q1 25 | $13.2B | $5.8B | ||
| Q4 24 | $13.1B | $5.9B | ||
| Q3 24 | $12.8B | $5.8B | ||
| Q2 24 | $12.2B | $5.7B | ||
| Q1 24 | $11.9B | $5.7B |
| Q4 25 | 11.49× | 0.19× | ||
| Q3 25 | 9.74× | — | ||
| Q2 25 | 12.14× | — | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | — | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — | ||
| Q1 24 | 181.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $141.0M | $417.3M |
| Free Cash FlowOCF − Capex | $96.0M | $379.8M |
| FCF MarginFCF / Revenue | 6.4% | 25.4% |
| Capex IntensityCapex / Revenue | 3.0% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $538.0M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $141.0M | $417.3M | ||
| Q3 25 | $264.0M | $402.6M | ||
| Q2 25 | $220.0M | $263.6M | ||
| Q1 25 | $75.0M | $44.1M | ||
| Q4 24 | $390.0M | $75.2M | ||
| Q3 24 | $141.0M | $188.4M | ||
| Q2 24 | $332.0M | $-95.6M | ||
| Q1 24 | $76.0M | $-308.6M |
| Q4 25 | $96.0M | $379.8M | ||
| Q3 25 | $218.0M | $354.5M | ||
| Q2 25 | $181.0M | $219.8M | ||
| Q1 25 | $43.0M | $-12.3M | ||
| Q4 24 | $335.0M | $-17.3M | ||
| Q3 24 | $99.0M | $54.7M | ||
| Q2 24 | $300.0M | $-205.5M | ||
| Q1 24 | $30.0M | $-465.1M |
| Q4 25 | 6.4% | 25.4% | ||
| Q3 25 | 13.6% | 25.1% | ||
| Q2 25 | 11.4% | 16.7% | ||
| Q1 25 | 2.8% | -1.1% | ||
| Q4 24 | 21.0% | -1.5% | ||
| Q3 24 | 6.3% | 5.5% | ||
| Q2 24 | 18.7% | -22.1% | ||
| Q1 24 | 1.8% | -61.9% |
| Q4 25 | 3.0% | 2.5% | ||
| Q3 25 | 2.9% | 3.4% | ||
| Q2 25 | 2.4% | 3.3% | ||
| Q1 25 | 2.1% | 5.0% | ||
| Q4 24 | 3.5% | 8.2% | ||
| Q3 24 | 2.7% | 13.3% | ||
| Q2 24 | 2.0% | 11.8% | ||
| Q1 24 | 2.8% | 20.8% |
| Q4 25 | — | 6.28× | ||
| Q3 25 | 1.65× | 3.22× | ||
| Q2 25 | 1.52× | 2.79× | ||
| Q1 25 | 0.86× | 34.71× | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 1.70× | — | ||
| Q1 24 | 0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
